摘要
目的研究早期应用辛伐他汀对急性冠脉综合征患者血脂、稳定斑块及减少炎症反应、缺血事件发生情况的影响。方法采用随机对照的方法,将72例急性冠脉综合征患者分为他汀治疗组(辛伐他汀10mg/d,n=36)和常规治疗组(n=36);治疗前后分别测定血清高敏C-反应蛋白(hs-CRP)、血浆白细胞介素-6(IL-6)水平和总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平。结果(1)他汀治疗组治疗12周后血清hs-CRP、血浆IL-6和血脂水平均较治疗前明显降低(P<0.01),常规治疗组除血清hs-CRP、血浆IL-6水平降低外(P<0.05),其他各项指标均无变化。(2)与常规治疗组比较,他汀治疗组缺血事件发生率明显下降(χ2=3.86,P<0.05)。结论早期应用辛伐他汀治疗对急性冠脉综合征患者既有稳定斑块减少炎症反应作用,又有降低缺血事件发生的作用,为防治急性心血管事件提供新的途径。
Objective To study the effect of early application of simvastatin on the blood liquid, stable plaque,lower inflammation and the incidence of ischemic events in coronary syndrome. Methods 72 cases of the patients of coronary syndrome were divided into simvastatin treatment group（ simvastatin 10mg/d, n = 36） and normal treatment group （n = 36） ; the level of serum C-reactive protein（hs-CRP）, plasma interleukin -6 （ IL-6 ）, serum total cholesterol （TC）, triglyeeride （TG）, low density lipoprotein cholesterol （ LDL-C ） and high density lipoprotein cholesterol（ HDL-C ） were determined before and after treatment. Results （1）After 12 weeks treatmeat, the level of serum hs-CRP, IL-6 and blood liquid of simvastatin group decreased significantly（ P 〈 0.01 ）; serum hs-CRP and plamsa IL-6 of normal group decreased（P〈 0.05 ）, the other index had no change. （ 2）The incidence of ischemic events of simvastatin group decreased significantly compared with normal treatmeat group（ x^ 2= 3.86,P〈 0.05）. Conclusion Early application of simvastatin in coronary syndrome have the advantages of stable plaque, lower inflammation and the incidence of ischemie events,supply the new method to prevent the incidence of acute cardicular incidents.
出处
《中国现代医生》
2008年第31期15-16,36,共3页
China Modern Doctor
